Kornimate/medical-research-clean huggingface dataset:
clinical, immunological, genomic, virological and bioethical actors of covid-19

Conditions: Covid19

Summary: the stop-coronavirus project is an integrated and multidisciplinary study that aims to analyze the impact that various factors have on the evolution and prognosis of the current covid-19. clinical presentation, immunological markers, therapeutic strategies, host and virus genomics, and bioethical considerations will be analyzed with a prospective multicenter cohort of patients with a diagnosis of covid-19.

this project led my dr aguado garcia, has established 8 work parckages (wp) to analyze factors involved in the impact of covid-19. wp that correspond to university hospital fundacion jimenez diaz are described in this register across different objectives: wp 3 (dr ayuso garcía) is aimed to analyze the genetic markers of host susceptibility associated with clinical evolution of covid-19. wp 6 (dr ruiz hornillos) will study the socio-economic and bioethical repercussions of covid-19. wp 7 (dr perales) will analyze the complexity of the spectrum of sars-cov-2 mutants and their possible association with the evolutionary course of covid-19 this project will guide and individualize the clinical and therapeutic approach to covid-19 and mitigate the health and social impact of the pandemic.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of covid-19 (positive rt-pcr for sars-cov-2 in respiratory sample). exclusion criteria: * suspected coronavirus infection without diagnostic confirmation

Keywords: genomics bioethics sars-cov-2
preliminary evaluation of two rapid diagnostic test prototypes for strongyloides stercoralis infection

Conditions: Strongyloides Stercoralis Infection

Summary: single center, no profit experimental study on sera available in the tropica biobank.


Eligibility criteria:
inclusion criteria: * serum from immigrants from s. stercoralis endemic countries (i.e. individuals from africa, latin america, south-east asia and western pacific regions); * serum with a matched result of apc and/or pcr for s. stercoralis (i.e. the latter test/s done in the same day or ±30 days from the collection of the serum) and of serology assays (ifat and/or elisa) in use in our laboratory. exclusion criteria: * unavailable/insufficient quantity of serum * serum from individuals who received treatment with ivermectin in the previous 6 months.
peripheral arterial insufficiency associated with hiv/aids

Conditions: Arterial Insufficiency; Acquired Immunodeficiency Syndrome; HIV

Summary: the purpose of this study is to determine the risk factors associated with the occurrence of arterial insufficiency in patients with hiv / aids, and to identify the prevalence of this disease. the estimated prevalence is 10%, similar to that reported in the general population.

a case study nested in a cohort of patients with hiv / aids at instituto nacional de ciencias médicas y nutrición salvador zubirán, mexico, with a cohort of 1500 patients , a sample size of 206 individuals was calculated. data collection was performed in a prospective cross shape. during the interview, written informed consent for inclusion in the study, along with a standard query of vascular surgery in which the patient's history as well as cardiovascular risk factors. also, a vascular physical examination including palpation of pulses in upper and lower extremities (brachial, radial, ulnar, femoral, popliteal, posterior tibial and dorsalis pedis), femoral murmurs search and determining ankle / brachial indexes with a standardized method. in determining the abi was counted with a doppler ultrasound 8 mhz, transducer gel and a sleeve for manual measurement of blood pressure, 20% longer than the largest diameter of the arm circumference. if the patient is diagnosed with, symptomatic or asymptomatic arterial insufficiency, abi measurements were performed at rest and effort, plus pressure index finger-arm or plethysmography. patients with altered rates were followed in vascular surgery care. the data were recorded in a single database unique protected by password. the results were analyzed using the statistical program stata v 9.0.

Eligibility criteria:
inclusion criteria: * patients with hiv / aids are included in active consultation of infectious diseases incmnsz and sign informed consent. exclusion criteria: * patients who do not wish to participate in the study and those who did not complete their interview and vascular physical examination.

Keywords: arterial insufficiency human immunodeficiency virus atherosclerosis ankle-brachial index haart
carotid plaque length to predict cardiovascular events

Conditions: Coronary Artery Disease

Summary: this multicenter study involved 5 hospitals (changhai hospital; yueyang hospital of shanghai university of traditional chinese medicine; gongli hospital; putuo hospital of shanghai university of traditional chinese medicine; no. 904 hospital of the pla joint logistics support force wuxi). the study enrolled 3000 patients for suspected cad who referred to coronary angiography from january 2017 through december 2018.

patients with coronary artery disease who were confirmed by coronary angiography were eligible for the study. carotid ultrasonography was performed before coronary angiography, and carotid intima-media thickness (imt), maximum thickness and length of all plaques were measured.

Eligibility criteria:
inclusion criteria: * patients≥18 years old, those who underwent carotid ultrasonography and first coronary angiography simultaneously. exclusion criteria: * patients with known coronary artery disease, previous coronary or carotid revascularization, missing carotid ultrasound or coronary angiography results.

Keywords: carotid artery ultrasound carotid plaque coronary artery disease
effects of acute intake of flavanols on cerebral oxygenation and cognition in young male adults

Conditions: Healthy

Summary: the study evaluates the impact of one acute dose of cocoa flavanols on brain oxygenation during a hypercapnia challenge, as well as impact on cognitive performance in young healthy males. it further assesses the impact of flavanols on peripheral vascular function, as measured by brachial flow-mediated dilation (fmd). all participants received a high-flavanol cocoa intervention (185.5 mg of flavanols (-)-epicatechin and (+)- catechin) and a low-flavanol cocoa intervention (\< 4 mg of flavanols). it is hypothesized that the high-flavanol intervention increases cerebral oxygenation during hypercapnia and vascular function in comparison to the low-flavanol intervention.

cocoa flavanols have been shown to be protective against vascular disease in humans, as evidenced by improvements in peripheral endothelial function (as measured by brachial flow-mediated dilatation, fmd). there is also emerging evidence suggesting that flavanol-rich diets protect against cognitive aging, but mechanisms remain elusive. in this study the investigators suggest that such mechanisms might be associated with benefits within the brain vasculature. the aim of the present study was therefore to determine whether intake of flavanols enhances cerebral oxygenation in frontal cortical areas of the brain during a hypercapnia challenge (which is a well-established biomarker of vascular reactivity in the brain) to a greater extent than a low-flavanol intervention in young healthy adults.

Eligibility criteria:
inclusion criteria: * male * 18-45 years old exclusion criteria: * smokers * hypertensive * with history of cerebrovascular, cardiovascular or respiratory disease * allergies or intolerances to ingredients present in cocoa powders * taking long-term medication (e.g., hyperlipidaemia) * on antibiotics for the previous 3 months before enrollment * suffering from blood-clotting disorders * known infections at the time of the study * on a weight-reducing regimen

Keywords: flavanol cocoa brain oxygenation vascular cognition hypercapnia functional near-infrared spectroscopy
a study of bms-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors

Conditions: Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Microsatellite Stable Colorectal Cancer; Non-Small-Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Urothelial Carcinoma; Pancreatic Adenocarcinoma; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms

Summary: the purpose of this study is to assess the safety, tolerability, and recommended dose(s) of bms-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. this study is a first-in-human (fih) study of bms-986340 in participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis * measurable disease per response evaluation criteria in solid tumors (recist) v1.1 and at least 1 lesion accessible for biopsy. fine needle biopsy, cytology, and bone lesion biopsies are not acceptable. * eastern cooperative oncology group performance status of 0 or 1 * radiographically documented progressive disease on or after the most recent therapy * received standard-of-care therapies, (except for part 1c, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated * advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant exclusion criteria: * women who are pregnant or breastfeeding * primary central nervous system (cns) malignancy * untreated cns metastases * leptomeningeal metastases * concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment * active, known, or suspected autoimmune disease * condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment * prior organ or tissue allograft * uncontrolled or significant cardiovascular disease * major surgery within 4 weeks of study drug administration * history of or with active interstitial lung disease or pulmonary fibrosis other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986340 cervical cancer crc first-in-human gej gastric/gastroesophageal junction adenocarcinoma hnscc microsatellite stable colorectal cancer mss crc nivolumab non-small-cell lung cancer nsclc scchn squamous cell carcinoma of head and neck carcinoma, renal cell urothelial carcinoma pancreatic adenocarcinoma melanoma ovarian neoplasms triple negative breast neoplasms
prevalence of depression and anxiety among breast cancer patients

Conditions: Depression; Anxiety; Breast Cancer

Summary: depression and anxiety in patients with breast cancer is serious comorbidity that affects the quality of life for patients, and their survival rates as they have poorer health outcomes. furthermore, patients' high psychological burden is linked to higher healthcare costs. the investigation of the depression and anxiety symptoms prevalence among newly diagnosed breast cancer patients will help to navigate the health policy adjustment and psycho-social support system requirements. this study aims to investigate the prevalence of depression and anxiety symptoms among newly diagnosed breast cancer patients in almaty, kazakhstan, and associated risk factors.


Eligibility criteria:
inclusion criteria: * female adults with confirmed diagnosis of breast cancer within the 6 months study enrollment * tnm stage i-iv * russian or kazakh language proficiency * ability to provide informed consent exclusion criteria: * current psychotic disorder, manic episode, serious neurological disorder, intellectual disability, or developmental disorder * current active suicidal ideation * referral to palliative care

Keywords: depression anxiety breast cancer prevalence beck depression inventory beck anxiety inventory
onabotulinumtoxin type a reconstitution with preserved versus preservative-free saline in chronic migraine.

Conditions: Chronic Migraine, Headache

Summary: a growing body of literature on the cosmetic use of onabotulinumtoxina has suggested that the use of preserved saline exerts a local anesthetic effect, and reduces the procedure discomfort when used in reconstitution in lieu of preservative-free saline. however, this has never been studied in chronic migraine. while reducing discomfort is a desirable target in all procedures, it has a special importance in the use of onabotulinumtoxina for chronic migraine due to the numerous injection locations each session (31 sites) and the ubiquity of scalp tenderness in this population. in addition, the pain during procedure is a known migraine trigger for many of these patients. we hypothesize that preserved saline (known as bacteriostatic saline) produces lower procedure-related discomfort when used as a dissolving solution for onabotulinumtoxina in individuals with chronic migraine as opposed to using preservative-free saline. in addition, we hypothesize that reduction of procedure-relate pain during the injections will also result in reduced migraine/headache attacks in the week immediately following the procedure.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of chronic migraine receiving fda-approved treatment with onabotulinumtoxina injection as per standard protocol. standard protocol consists of 31 injection sites, with total dose ranging from 155 u to 195u. exclusion criteria: * subjects whom onabotulinumtoxina injections deviate from standard protocol for any reason, such as head/neck infection, head deformity, recent surgery...etc.

Keywords: migraine onabotulinumtoxin a botox reconstitution saline
a study of ptx-200 (triciribine) plus cytarabine in refractory or relapsed acute leukemia

Conditions: Acute Leukemia

Summary: a phase i-ii open label study of ptx-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

study design: phase i/ii study the phase i study is open-label with four increasing dose levels for up to four 21-day cycles. safety and activity will be evaluated at the end of each cycle. the phase ii study is open label with administration of the recommended phase dose of ptx-200 for up to four 21-day cycles. ptx-200 will be co-administered with cytarabine in both the phase i and phase ii parts of the study.

Eligibility criteria:
inclusion criteria: * pathologic confirmation of the diagnosis of aml, all (acute lymphoblastic leukemia), or blast-phase cml (chronic myelogenous leukemia) * age ≥ 18 years * ecog performance status 0-2 * patients must be able to give adequate informed consent exclusion criteria: * hyperleukocytosis with ≥ 30,000 leukemic blasts/µl blood (hydroxyurea permitted up to 24 hours prior to beginning study drugs) * uncontrolled disseminated intravascular coagulation (dic) * uncontrolled diabetes mellitus * active, uncontrolled infection
safety and tolerability of chitosan-n-acetylcysteine eye drops in healthy young volunteers

Conditions: Dry Eye Syndromes

Summary: the "dry eye syndrome" des is a highly prevalent ocular disease, in particular in the elderly population. one mainstay of therapy for patients suffering from des is the use of topically administered lubricants. however, despite many efforts, no "ideal" formulation has yet been found. recently, croma pharma has introduced chitosan-n-acetylcysteine eye drops, designed for treatment of symptoms related to des. chemically, chitosan is a polycationic biopolymer with favourable biological properties such as high biocompatibility and low toxicity. additionally, the new formulation comprises n-acetylcysteine, which has been used in ophthalmology because of its mucolytic properties for several years. based on theoretical considerations, one can hypothesize that the new chitosan derivative may show an increased adhesion to mucins of the ocular surface and may therefore be particularly beneficial in reducing the symptoms associated with des.


Eligibility criteria:
inclusion criteria: * men and women aged between 18 and 45 years * normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings, ametropia \< 6 dpt. exclusion criteria: * participation in a clinical trial in the 3 weeks preceding the study * abuse of alcoholic beverages * symptoms of a clinically relevant illness in the 3 weeks before the first study day * ametropia of 6 or more dpt. * pregnancy

Keywords: dry eye syndromes
study of patients with acute renal failure on cvvh

Conditions: Renal Failure

Summary: acute kidney failure is common in children in the pediatric intensive care unit (picu). you are being asked to participate in this study because your child is being treated for kidney failure with continuous veno-venous hemofiltration (cvvh). cvvh is a continuous, gentle form of removing excess fluids and small wastes from the blood, similar to kidney dialysis (artificial kidney). it is an accepted therapy for temporary support of kidney failure. in some patients with acute kidney failure, beginning cvvh is followed by a temporary decrease of urine output. the reason why this happens is currently unknown. the purpose of this study is to determine why this happens.

acute renal failure is common in children in the pediatric intensive care unit. renal replacement therapies such as peritoneal dialysis (pd), intermittent hemodialysis (ihd), and continuous venovenous hemofiltration (cvvh) have been used in the management of acute renal failure. cvvh is becoming increasingly utilized in pediatric acute renal failure. however, in patients who have acute renal failure, the institution of cvvh is often followed by a progression to oliguria or anuria. the underlying pathophysiology of this change is unknown. we believe that this progression is influenced by changes in the renin-angiotensin axis, cytokine response, and other modifiers of renal hemodynamics. by serially measuring components of those systems, this study will attempt to elucidate the pathophysiology of the decreased urine output seen with institution of cvvh. once this process is understood, future studies should focus on prevention and treatment of this complication. general hypothesis the decrease in urine output seen after the initiation of cvvh is associated with increased angiotensin converting enzyme (ace) levels, increased renin activity, increased angiotensin ii levels, increased atrial naturetic peptide (anp) levels, increased endothelin-1 levels, increased arginine vasopressin (avp) levels, and alterations of cytokine levels and modulators of apoptosis.

Eligibility criteria:
inclusion criteria: the general goal of patient selection is to enroll all children for whom cvvh is instituted. inclusion criteria: age * 6 months -18 years old * patients less than 6 months of age on ecmo (addendum #1) indication for cvvh: including, but not limited to : * acute renal failure * oliguria * anuria * hyperkalemia * severe acidemia * azotemia * pulmonary edema * uremic complications * severe electrolyte abnormalities * drug overdose with a filterable toxin * anasarca * rhabdomyolysis exclusion criteria: * age * less than 6 months old (unless on ecmo) * greater than 18 years old weight * less than 5 kilograms (unless on ecmo) location * cardiac intensive care unit * neonatal intensive care unit non-adherence: inability or unwillingness of the legal guardian to provide consent or inability or unwillingness of the child to provide assent

Keywords: acute renal failure contiuous veno venous hemofiltration
characteristics of the intestinal microbiota in patients with cancer

Conditions: Oncology

Summary: in order to understand how the intestinal microbiota plays a role in the effectiveness of an anti-cancer treatment by an immune control point inhibitor, this study aims to constitute a catalog of microbial genes of a patient with cancer. this catalog will help to characterize the intestinal microbiota of cancer patients and to be able to use this catalog as a reference tool for screening the microbiota of patients treated with immune control point inhibitors. to produce this catalog, five types of cancer were selected: non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, breast cancer and prostate cancer. the metagenomic analysis of a group of five different types of cancers introduces a lot of heterogeneity which is favorable to the richness of a catalog. for non-small cell lung cancer treated with immune control point inhibitors, two stool collections will be performed per patient (one stool collection before setting up an immune control point inhibitor and one collection after one month of being inhibited of immune control point) to assess the impact of the immune control point inhibitor on the microbiota (pilot study). for this study, two stool collection tubes containing different preservative solutions will be used (one rnalater tube and one dmso-edta tube for dimethylsulfoxide-ethylene diamine tetraacetic acid). in parallel, we will also collect samples of serum and plasma to evaluate, in a second step, protein markers in circulating blood.

primary objective: develop a catalog of microbial genes dedicated to oncology (onco catalog) by sequencing stool specimens from patients with cancer.

Eligibility criteria:
inclusion criteria: * men or women between 18 and 75 years of age. * patients with one of the following types of cancer: non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, prostate cancer and glioblastoma * patients with informed consent to participate in the study. * affiliation to the social security system exclusion criteria: * for patients with hepatocellular cancer, patients infected with the human immunodeficiency virus (hiv) * patients who are unable to understand, read and / or sign informed consent * patients who can not collect / send stools for geographical, social or psychological reasons * patients with previous cancer in the 5 years preceding this study * persons benefiting from a system of protection for adults (including guardianship and curatorship) * pregnant or nursing women * patients with another synchronous tumor * patients with fecal transplant * patients with chronic inflammatory bowel disease (ibd) * patients having had in the 3 months preceding the collection of stool: colonoscopy, bariatric surgery, surgical removal of a segment of the small intestine (enteritomy or enterostomy), parenteral nutrition. * patients who had had antibiotic therapy within 1 month before stool collection

Keywords: intestinal microbiota, microbial genes, oncology